Welcome Message
Welcome to the EASL Liver Cancer Summit 2025 - the premier event for liver cancer research and practice, taking place in the magnificent capital of France: Paris. Will this year’s meeting be worth attending? The answer is a loud and undeniable YES! We are excited to welcome you to Paris in February 2025.
You might wonder why we are so enthusiastic. The field of primary liver cancer has seen remarkable advancements recently, transforming it into a rapidly evolving and dynamic area of study. For nearly 15 years since 2008, very little change took place in treatment strategies for hepatocellular carcinoma and cholangiocarcinoma, the two most common primary liver malignancies. However, recent years have witnessed the arrival of new treatment regimens that are reshaping standard therapeutical paradigms. Immunotherapy has shown benefits not only for advanced hepatocellular carcinoma, but also for cholangiocarcinoma, and antiangiogenics are no longer the default. Additionally, the potential of objective response with systemic therapy is challenging the established roles of surgical and locoregional treatment strategies in hepatocellular carcinoma, thanks to new combination or sequential therapies and revised approaches. Artificial intelligence is poised to enhance our diagnostic capabilities for liver tumours, but users must be aware of their limitations and risks. Meanwhile, basic science is uncovering new therapeutic targets and tumour classifications.
With all these innovations emerging at an accelerated pace, this international event is crucial for anyone wishing to stay at the forefront of liver cancer research and treatment. We eagerly anticipate your presence in Paris at the EASL Liver Cancer Summit on 20-22 February 2025.
Julien Calderaro, Rocio IR Macias and Fabio Piscaglia
EASL Liver Cancer Summit 2025 Organising Committee
Fabio Piscaglia
Italy
Fabio Piscaglia is Professor of Internal Medicine at the University of Bologna and Director of the Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases at the Policinico di S.Orsola, Bologna, Italy. He has been President of the European Federation of Societies for Ultrasound in Medicine and Biology in the term 2011-2013 and the main fields of interest of his research group are diagnostic and therapeutic management of HCC.
Julien Calderaro
France
Julien Calderaro is Full Professor in the Department of Pathology of Henri Mondor University Hospital in Créteil, France. He is specialized in the field of liver diseases and tumors diagnosis. His works noticeably led to the establishment of a refined morphomolecular classification of liver cancer. He now focuses his research on the immune micro-environment of liver cancers and develops innovative, artificial-intelligence based approaches to extract meaningful prognostic and molecular data from digital histological slides.
Rocio IR Macias
Spain
Rocio IR Macias is Full Professor in the Department of Physiology and Pharmacology at the University of Salamanca, Spain. She is interested in the identification of non-invasive biomarkers for the early diagnosis of liver cancers, especially cholangiocarcinoma, as well as in identifying markers to predict response to drug treatment and in designing strategies to circumvent chemoresistance. He chairs the COST Action Precision-BTC-network. She is the Chair of the COST Action Precision-BTC-network.